ACS Medicinal Chemistry Letters · 2020 · 11 citations · 32 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryProdrug DesignRheumatologyAnti-inflammatory PharmacologyInflammatory ArthritisReactive Oxygen SpeciesRedox-activated ProdrugsRheumatoid ArthritisCollagen-induced ArthritisCovalent InhibitorsCovalent Kinase InhibitorsJak InhibitorsJak-stat Signaling PathwayReactive Oxygen Species-responsive ProdrugsReactive Oxygen Species-triggered ProdrugsRheumatoid Arthritis Models
Selective inhibition of Janus kinases (JAKs) is an arising strategy in drug discovery. Covalent inhibitors targeting a unique cysteine in JAK3 exhibit ultraselectivity among JAK family members. However, safety and tissue specific concerns still remain. A prodrug of a known JAK3 covalent inhibitor sensitive to H2O2 was designed and synthesized and its therapeutic effect was evaluated in the CIA (collagen-induced arthritis) mice model of RA (rheumatoid arthritis). The prodrug strategy relied on the introduction of a hydrogen peroxide-sensitive borate trigger group to avoid random covalent binding to thiol functionalities in biomacromolecules. The results show that the prodrug can be activated and released under pathophysiological concentration of H2O2. In addition, the prodrug demonstrated stability to the physiological environment. In comparison to the parent compound, the prodrug showed a similar therapeutic effect in the CIA model but notably exhibited lower toxicity and a larger therapeutic window.
32
Lee Honigberg, Ashley M. Smith, Mint Sirisawad et al. · Proceedings of the National Academy of Sciences · 2010 · 1.5K citations · Full text
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd, Bonnie K. Harrington, Susan O’Brien et al. · New England Journal of Medicine · 2015 · 891 citations · Full text
Aminoferrocene-Based Prodrugs Activated by Reactive Oxygen Species
Helen Hagen, Paul Marzenell, Elmar Jentzsch et al. · Journal of Medicinal Chemistry · 2011 · 257 citations